Receptor activator of NF-κB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147

Cancer Research

Volumn 70, Issue 15, 2010, Pages 6150-6160

  Rucci, Nadia ^a   Millimaggi, Danilo ^a   Mari, Marianna ^a   Del Fattore, Andrea ^a   Bologna, Mauro ^a   Teti, Anna ^a   Angelucci, Adriano ^a   Dolo, Vincenza ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD147 ANTIGEN; GELATINASE B; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SMALL INTERFERING RNA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE ATROPHY; BREAST CANCER; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; UPREGULATION;

ANIMALS; ANTIGENS, CD147; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; MICE, NUDE; RANK LIGAND; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77955357297     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2758     Document Type: Article

References (43)

1. Biswas C, Zhang Y, DeCastro R, et al. The human tumor cell-derived collagenases stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 1995;55:434-9.
2. Suzuki S, Sato M, Senoo H, Ishikawa K. Direct cell-cell interaction enhances pro-MMP2 production and activation in co-colture of laryngeal cancer cells and fibroblasts: involvement of EMMPRIN and MT1-MMP. Exp Cell Res 2004;293:259-66.
3. DeCastro R, Zhang Y, Guo H, et al. Human keratinocytes express EMMPRIN, an extracellular matrix metalloproteinase-inducer. J Invest Dermatol 1996;106:1260-5.
4. Marmorstein AD, Bonhila VL, Chiflet S, Neilla JM, Rodriguez-Boulan E. The polarity of the plasma membrane protein RETPE2 in the retinal pigment epithelium is developmentally regulated. J Cell Sci 1996;109:3025-34. (Pubitemid 27029272)
5. Finneman SC, Marmostein AD, Neill JM, Rodriguez-Boulan E. Identification of the retinal pigment epithelium protein RET-PE2 as CE-9/OX-47, a member of the immunoglobulin superfamily. Invest Ophthalmol Vis Sci 1997;38:2366-74. (Pubitemid 27446954)
6. Yan L, Zucker S, Toole BP. Role of the multifunctional glycoprotein, emmprin (basigin, CD147), in tumour progression. Thromb Haemost 2005;93:199-204. (Pubitemid 40253722)
7. Reimers N, Zafrakas K, Assmann V, et al. Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res 2004;10:3422-8.
8. Gabison EE, Hoang-Xuan T, Mauviel A, Menashi S. EMMPRIN/ CD147, an MMP modulator in cancer, development and tissue repair. Biochimie 2005;87:3861-6.
9. Caudroy S, Polette M, Nawrocki-Raby B, et al. EMMPRIN-mediated MMP regulation in tumor and endothelial cells. Clin Exp Metastasis 2002;19:697-702. (Pubitemid 36092265)
10. Sun J, Hemler ME. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res 2001;61:2276-81. (Pubitemid 32692059)
11. Tang Y, Nakada MT, Kesavan P, et al. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 2005;65:3193-9.
12. Millimaggi D, Mari M, D'Ascenzo S, Giusti I, Pavan A, Dolo E. Vasculogenic mimicry of human ovarian cancer cells: role of CD147. Int J Cancer 2009;35:1423-8.
13. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243-9s.
14. Esteve FR, Roodman GD. Pathophysiology of myeloma bone disease. Best Pract Res Clin Haematol 2007;20:613-24.
15. Engel J, Eckel R, Kerr J, et al. The process of metastatisation for breast cancer. Eur J Cancer 2003;39:1794-806.
16. Clezardin P, Teti A. Bone metastasis: pathogenesis and therapeutic implications. Clin Exp Metastasis 2007;24:599-608. (Pubitemid 50003596)
17. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Mol Cancer Ther 2007;6:2609-17.
18. Siclari VA, Guise TA, Chirgwin JM. Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer Metastasis Rev 2006;25:621-33.
19. Crampton SP, Davis J, Hughes CC. Isolation of umbilical vein endothelial cells (HUVEC). J Vis Exp 2007;3:183.
20. Zucker S, Hymowitz M, Rollo EE, et al. Tumorigenic potential of extracellular matrix metalloproteinase inducer (EMMPRIN). Am J Pathol 2001;158:1921-8.
21. Marzia M, Sims NA, Voit S, et al. Decreased c-src expression enhances osteoblast differentiation and bone formation. J Cell Biol 2000;151:311-20.
22. Angelucci A, Gravina GL, Rucci N, et al. Evaluation of metastatic potential in prostate carcinoma: an in vivo model. Int J Oncol 2004;25:1713-20.
23. Rucci N, Recchia I, Angelucci A, et al. Inhibition of protein kinase c-Src reduces breast cancer metastases and increases survival in mice. J Pharmacol Exp Ther 2006;318:161-72.
24. Damsker JM, Okwumabua I, Pushkarsky T, Arora K, Bukrinsky MI, Constant SL. Targeting the chemotactic function of CD147 reduces collagen-induced arthritis. Immunology 2008;126:55-62.
25. Albini A, Iwamoto Y, Kleinman HK, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987;47:3239-45. (Pubitemid 17082655)
26. Muraoka K, Nabeshima K, Murayama T, Biswas C, Koono M. Enhanced expression of tumor-cell-derived collagenase-stimulatory factor in urothelium carcinomas: its useful as a tumor marker for bladder cancers. Int J Cancer 1993;55:19-26.
27. Polette M, Gilles C, Marchand V, et al. Tumor collagenase stimulatory factor (TCSF) expression and localization in human lung and breast cancers. J Histochem Cytochem 1997;45:703-7.
28. Van den Oord JJ, Paemen L, Opdenakker G, de Wolf-Peeters C. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol 1997;151:665-70. (Pubitemid 27385597)
29. Caudroy S, Polette M, Tournier JM, et al. Expression of the extracellular matrix metalloproteinase inducer (EMMPRIN) and the matrix metalloproteinase-2 in bronchopulmonary and breast lesions. J Histochem Cytochem 1999;47:1575-80.
30. Yang JM, O'Neill P, Jin W, et al. Extracellular matrix metalloproteinase inducer (CD147) confers resistance of breast cancer cells to anoikis through inhibition of bim. J Biol Chem 2006;281:9719-27.
31. Zou W, Zhu H, Wu X. Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to paclitaxel in HO-8910pm cells. Cancer Lett 2006;248:211-8. (Pubitemid 46330554)
32. Li QQ, Wang WJ, Xu JD, Chen Q, Yang JM, Xu ZD. Up-regulation of CD147 and matrix metalloproteinase-2, -9 induced by P-glycoprotein substrates in multidrug resistant breast cancer cells. Cancer Sci 2007;98:1767-74.
33. Dean NR, Newman JR, Helman EE, et al. Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer. Clin Cancer Res 2009;15:4058-65.
34. Marieb EA, Zoltan-Jones A, Li R, et al. Emmprin promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production. Cancer Res 2004;64:1229-32.
35. Roodman GD. Mechanisms of bone metastasis. N Eng J Med 2004;350:1655-64.
36. Guise TA, Mohammad KS, Clines G, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006;12:6213-6s.
37. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76.
38. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003;8:638-49.
39. Si AI, Huang L, Xu J, Kumta SM, Wood D, Zheng MH. Expression and localization of extracellular matrix metalloproteinase inducer in giant cell tumor of bone. J Cell Biochem 2003;89:1154-63. (Pubitemid 36959383)
40. Wucherpfennig AL, Li YP, Stetler-Stevenson WG, Rosenberg AE, Stashenko P. Expression of 92 kD type IV collagenase/gelatinase B in human osteoclasts. J Bone Miner Res 1994;9:549-56. (Pubitemid 24090338)
41. Voorzanger-Rousselot N, Juillet F, Mareau E, Zimmermann J, Kalebic T, Garnero P. Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a cross sectional and longitudinal evaluation. Br J Cancer 2006;95:506-14.
42. Nakagawa M, Kaneda T, Arakawa T, et al. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 2000;473:161-4.
43. Aldridge SE, Lennard TWJ, Williams JR, Birch MA. Vascular endothelial growth factor acts as an osteolytic factor in breast cancer metastases to bone. Br J Cancer 2005;92:1531-7.